Does Nubeqa Cause Cognitive Difficulty?
Nubeqa (darolutamide) does NOT cause clinically significant cognitive difficulty and demonstrates a favorable cognitive safety profile compared to other androgen receptor inhibitors.
Evidence from FDA Drug Label
The FDA-approved prescribing information for Nubeqa does not list cognitive impairment, memory problems, or cognitive difficulty as warnings, precautions, or common adverse events 1. The primary safety concerns highlighted are ischemic heart disease and seizure risk, but notably, cognitive dysfunction is absent from the documented adverse event profile.
Clinical Trial Evidence on Cognitive Function
Direct Cognitive Assessment Studies
The ODENZA trial (2024) provides the highest-quality evidence directly addressing cognitive function with darolutamide 2. This randomized crossover study specifically measured cognitive outcomes in 249 men with metastatic castration-resistant prostate cancer:
- Darolutamide showed a moderate BENEFIT in episodic memory compared to enzalutamide
- Better acquisition of new information (effect size = 0.5)
- Better recall after brief delay (effect size = 0.3)
- Patients reported significantly less fatigue with darolutamide (2.7) versus enzalutamide (3.3) on the Brief Fatigue Inventory
- No differences in depression, seizures, or falls between treatments
Cerebral Blood Flow Studies
A 2023 phase I study using arterial spin-label MRI in healthy volunteers demonstrated the mechanistic basis for darolutamide's cognitive safety 3:
- Darolutamide showed NO significant changes in cerebral blood flow in cognition-relevant brain regions
- Enzalutamide caused significant 5.2-5.9% reductions in temporo-occipital cortices
- Enzalutamide reduced blood flow in dorsolateral prefrontal cortices (areas critical for executive function)
- These findings correlate with darolutamide's low blood-brain barrier penetration
Comparative Safety Data
Multiple indirect comparison studies consistently show darolutamide has lower rates of CNS-related adverse events compared to other second-generation androgen receptor inhibitors 4, 5, 6:
- Significantly lower rates of mental impairment versus enzalutamide
- Lower rates of dizziness and fatigue
- No increased seizure risk in clinical development
Major Clinical Trials Safety Profile
In the pivotal ARASENS trial (1,306 patients with metastatic hormone-sensitive prostate cancer), the most common adverse events with darolutamide were 7:
- Alopecia (40.5%)
- Neutropenia (39.3%)
- Fatigue (33.1%)
- Anemia (27.8%)
Notably absent: cognitive impairment, confusion, or memory problems
Clinical Bottom Line
Darolutamide should be considered the preferred androgen receptor inhibitor when cognitive function is a concern, particularly in:
- Older patients at higher baseline cognitive risk
- Patients with pre-existing mild cognitive impairment
- Patients whose occupation or quality of life depends on preserved cognitive function
- Patients who have experienced cognitive side effects with other antiandrogens
Important Caveats
- While darolutamide has superior cognitive safety, patients should still be monitored for any CNS effects
- The drug does carry warnings for seizure risk (though not specifically cognitive impairment) 1
- Individual patient responses may vary, but population-level data strongly favor darolutamide for cognitive preservation
The evidence consistently demonstrates that darolutamide's unique pharmacologic properties—particularly its minimal blood-brain barrier penetration—translate into a clinically meaningful advantage in preserving cognitive function compared to other agents in its class.